CKD & Osteoporosis Rx Revisited (7.25.2025)
Dr. Jack Cush reviews the news, journal and FDA updates from this past week on RheumNow.com.
Read Article
Detailed comprehensive overview of GLP-1RAs and SGLT2 inhibitors - their benefits w/ inflammatory conditions, & potential antiinflammatory effects. Bi-directional interplay between obesity, inflammation, and comorbid diseases https://t.co/oAQsuWVbZO https://t.co/SNqngATBtv
Dr. John Cush @RheumNow( View Tweet )
JAMA overview of Obstructive sleep apnea (OSA) - affects 1 billion worldwide. Treatment options: Positive Airway Pressure, Oral Appliance, Positional Therapy, Weight Loss, upper airway surgery. https://t.co/imrdsLAocG https://t.co/JEneFvyijN
Links:
Dr. John Cush @RheumNow( View Tweet )
40 kids w/ Psoriasis compared to 40 juvenile PsA pts. Those w/ jPsA were more likely to be:
- Obese/overweight (80 vs 17.5%)
- passive smoking (37.5 vs (25%)
- Signif higher ESR and CRP (P < 0.001)
- Nail PsO (65 vs 22%) https://t.co/3uBHnxZYC2 https://t.co/rW48EQta2s
Dr. John Cush @RheumNow( View Tweet )
From 1990 to 2021, the global burden of OA from high BMI increased markedly. YLD (years lived w/ disability) rates of OA attributable to high BMI increased from 34 to 50.6 per 100,000 - higher in females, correlated w/ Socio-demographic Index levels https://t.co/RjTJFNEbYm https://t.co/tIqmn9eLQ6
Dr. John Cush @RheumNow( View Tweet )
ICYMI: ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain
The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine.
Read Article
GLP 1 Receptor Agonists in axSpA
Dr. David Liew reviews POS1232 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/88Ms7ce7XX https://t.co/tt3qZH1hJT
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Proinflammatory Diet Increases Gout Risk
MedPage Today
Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated. Data from the two iterations of the Nurses' Health Study, in which more than 170,000 women were followed for more than two decades, indicated that diets scoring high on the Empirical Dietary
Read Article
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/2wloutoX8a
Dr. John Cush @RheumNow( View Tweet )
Multinational metanalyses of 24 studies & 1,173,410 participants shows alcohol increases risk of hyperuricemia (OR 1.51) and gout (OR 1.81) - more so in males > females. Little effect of age, country, study type, type of alcohol, Dx criteria in regression analyses. https://t.co/NSYTppcKzV
Dr. John Cush @RheumNow( View Tweet )
Dual pandemic in Africa.
Increasing lifestyle diseases and obesity, along with infections and malnutrition.
These may be reflected in rheumatic diseases too (if they could be studied in detail)
#EULAR2025 @RheumNow https://t.co/6ulMRxX8az
Links:
Bella Mehta @bella_mehta( View Tweet )
#EULAR2025 Abstr#OP0281 Not just shredding the weight but now also the pain! Another potential benefit of GLP-1 agonists - reducing symptoms of patients with Fibromyalgia. Propensity matched analysis using TrinetX database showed reduction on opiates, fatigue and pain @RheumNow https://t.co/oh6ecJmM5e
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#D2M_axSpA_saga 🇬🇷
Prevalence of D2M axSpA in 395 patients: 10.1%
Associated factors:
🔹️High disease activity at diagnosis
🔹️Comorbidities (high BMI, smoking, depression)
🔹️Unemployment
Kougkas et al.
POS#0121
#EULAR2025
@rheumnow https://t.co/vcPcTATTx5
Nelly ZIADE 🍀 @Nellziade( View Tweet )
EULAR 2025 – Day 2 Report
Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few
Read Article
🦵🏼💉LOSEIT study: liraglutide led to slight↑ in medial joint space width in knee OA vs placebo (0.22 vs 0.07 mm), but difference not statistically significant (p=0.17). More potent GLP-1RAs may be needed for greater improvement in structural knee OA
@RheumNow #EULAR2025 #OP0223
Mrinalini Dey @DrMiniDey( View Tweet )
The American Heart Association just published their alcohol recommendations today which line up with the report by the National Academies. Moderate EtOH intake, up to 7 drinks per week (1/day), is without risk (and may be beneficial for cardiovascular outcomes)
@American_Heart https://t.co/7c0IlmgZiv
Eric Topol @EricTopol( View Tweet )
MTX Fails Knee OA (6.6.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read Article
PPACMAN Consensus Recs. for CV risk in PSO/PSA published for Rheums/Derms/PCPs
- check BP, Wt, Lipids, Cr.
- Look for HTN, DM, smoking, obesity, metabolic synd.
- Risk stratify w/ hsCRP, Lipids
- Lifestyle management https://t.co/MkgYopTNAX https://t.co/fplKbua9Z2
Dr. John Cush @RheumNow( View Tweet )
PPACMAN Consensus Recs. for CV risk in PSO/PSA published for Rheums/Derms/PCPs
- check BP, Wt, Lipids, Cr.
- Look for HTN, DM, smoking, obesity, metabolic synd.
- Risk stratify w/ hsCRP, Lipids
- Lifestyle management https://t.co/MkgYopTNAX https://t.co/6yyxVIxpC0
Dr. John Cush @RheumNow( View Tweet )
Do SGLT2 and GLP-1 therapies have a role in Lupus?
Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA) were initially developed as glucose-lowering agents for the treatment of Type 2 Diabetes. Since their introduction, they have been noted to have a myriad of other benefits, including
Read Article
Risk Factors for Knee Osteoarthritis
New research from the University of Sydney reveals that obesity, having a knee injury and occupational risks such as shift work and lifting heavy loads are primary causes of knee osteoarthritis.
https://t.co/Kc686Zc8Xa https://t.co/ANyiE2pIxo
Dr. John Cush @RheumNow( View Tweet )
3-year, RCT of Mediteranean diet vs usual care in 924 older adults w/ metabolic syndrome & BMI > 27. Med. diet shows signif wt loss (3.4% vs 0.4%), w/ improved BMD (by DEXA) at year 3, especially in women. https://t.co/mllx6l1QnM https://t.co/I5e8PXX2oX
Dr. John Cush @RheumNow( View Tweet )
3-year, RCT of Mediteranean diet vs usual care in 924 older adults w/ metabolic syndrome & BMI > 27. Med. diet shows signif wt loss (3.4% vs 0.4%), w/ improved BMD (by DEXA) at year 3, especially in women. https://t.co/mllx6l1QnM https://t.co/CulO1Sschf
Dr. John Cush @RheumNow( View Tweet )
Vitamin D Headlines (5.9.2025)
Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy.
Read Article
Finish Birth Cohort followed since 1986, who were asymptomatic, found abnormal MRI knee findings, esp cartilage defects in the patellofemoral (56%) & tibiofemoral joints (25%) joints. Small/doubtful patellofemoral (52%) & tibiofemoral (17%) osteophytes seen. Most w/ High BMI. https://t.co/nQKREE4XfU
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
Comorbidities can pile up like a stack of blocks for people with rheumatoid arthritis (RA). At the time when RA is diagnosed, they already have more comorbidities than their peers, and after RA diagnosis they accumulate comorbidities faster than their peers.
Read Post
